ライフサイエンスコーパス: concurrent chemoradiotherapy

1 l carcinoma undergoing radiotherapy alone or concurrent chemoradiotherapy.

2 nts undergoing radiotherapy or sequential or concurrent chemoradiotherapy.

3 e consistent with toxicities associated with concurrent chemoradiotherapy.

4 early postoperative chemotherapy followed by concurrent chemoradiotherapy.

5 on chemotherapy did not preclude delivery of concurrent chemoradiotherapy.

6 o achieved more than 50% response went on to concurrent chemoradiotherapy.

7 emoradiotherapy (274 patients) or once-daily concurrent chemoradiotherapy (273 patients).

8 and randomly assigned to receive twice-daily concurrent chemoradiotherapy (274 patients) or once-dail

9 The addition of induction chemotherapy to concurrent chemoradiotherapy added toxicity and provided

10 rrent chemoradiotherapy with cisplatin-based concurrent chemoradiotherapy alone in patients with loca

11 rapy with either docetaxel or carboplatin or concurrent chemoradiotherapy alone with two cycles of bo

12 xicity and provided no survival benefit over concurrent chemoradiotherapy alone.

13 nt studies have suggested the superiority of concurrent chemoradiotherapy and the efficacy of paclita

14 atients did not receive more than 2 weeks of concurrent chemoradiotherapy and were not assessable for

15 ve a role for patients who initially receive concurrent chemoradiotherapy, and further study in this

16 ntified, and this has led to the adoption of concurrent chemoradiotherapy as a standard of care for t

17 ith advanced T-stage OPSCC who had completed concurrent chemoradiotherapy, bioradiotherapy, or radiot

18 Given the toxicity of concurrent chemoradiotherapy, careful selection of patie

19 Taxane-based concurrent chemoradiotherapy (CCR) for head and neck can

20 PET/CT scan before adjuvant radiotherapy or concurrent chemoradiotherapy (CCRT) could meaningfully i

21 Concurrent chemoradiotherapy (CCRT) for squamous cell ca

22 hibitor, added to, and in maintenance after, concurrent chemoradiotherapy (CCRT) in locally advanced

23 Concurrent chemoradiotherapy (CCRT) prevented involvemen

24 oesophageal cancer (EC) patients undergoing concurrent chemoradiotherapy (CCRT) remains uncertain.

25 neck squamous cell carcinoma (LAHNSCC) after concurrent chemoradiotherapy (CCRT).

26 ies have demonstrated the safety of adjuvant concurrent chemoradiotherapy (CRT) for locally advanced

27 d safety of palifermin in patients receiving concurrent chemoradiotherapy for advanced head and neck

28 cancer, or prevention of esophagitis during concurrent chemoradiotherapy for non-small-cell lung can

29 study of induction chemotherapy followed by concurrent chemoradiotherapy for organ preservation in p

30 Concurrent chemoradiotherapy has become a widely used me

31 gative (18)F-FDG PET or PET/CT results after concurrent chemoradiotherapy have a high negative predic

32 hedule of induction chemotherapy followed by concurrent chemoradiotherapy have been encouraging, and

33 Concurrent chemoradiotherapy improves cancer-related out

34 -intent treatment of locally advanced NSCLC, concurrent chemoradiotherapy improves local control and

35 Limited-stage disease should be treated with concurrent chemoradiotherapy in patients with good perfo

36 ot differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-st

37 9) demonstrated efficacy and tolerability of concurrent chemoradiotherapy in poor-risk stage III non-

38 daily gefitinib with radiation alone or with concurrent chemoradiotherapy in previously untreated pat

39 incorporate these agents with induction and concurrent chemoradiotherapy in stage III NSCLC.

40 Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB NSCLC is feas

41 Toxicities of concurrent chemoradiotherapy included grade 3 esophagiti

42 ad and neck squamous cell carcinoma (HNSCC), concurrent chemoradiotherapy is a widely accepted treatm

43 Concurrent chemoradiotherapy is associated with a one in

44 Concurrent chemoradiotherapy is standard treatment for p

45 Concurrent chemoradiotherapy is the standard of care for

46 Concurrent chemoradiotherapy is the standard of care in

47 In the patients who received previous concurrent chemoradiotherapy, median overall survival fo

48 of HART, mucosal toxicity, and the fact that concurrent chemoradiotherapy now seems more effective th

49 s more pronounced with the administration of concurrent chemoradiotherapy on study arms 2 and 3 (19%

50 based chemotherapies with or without upfront concurrent chemoradiotherapy or radiotherapy with curati

51 line-based chemotherapies and upfront use of concurrent chemoradiotherapy or radiotherapy.

52 in/etoposide [PE]; three cycles) followed by concurrent chemoradiotherapy (PE plus 45 Gy; 1.5 Gy twic

53 ute mucositis is a dose-limiting toxicity of concurrent chemoradiotherapy regimens for locally advanc

54 to improve patient access to curative intent concurrent chemoradiotherapy regimens.

55 carcinoma trial showed that cisplatin-based concurrent chemoradiotherapy resulted in a significantly

56 appropriate, standard treatment option, and concurrent chemoradiotherapy therapy is the most widely

57 Chemotherapy soon after surgery followed by concurrent chemoradiotherapy therapy was feasible; toler

58 During concurrent chemoradiotherapy, there was no difference in

59 Concurrent chemoradiotherapy using twice-daily radiation

60 Unfortunately, disease response to concurrent chemoradiotherapy varies among patients with

61 Unfortunately, disease response to concurrent chemoradiotherapy varies among patients with

62 Concurrent chemoradiotherapy was generally well tolerate

63 assigned to arm A, which involved immediate concurrent chemoradiotherapy with carboplatin area under

64 cil (TPF) induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin-based concur

65 therapy with three cycles of TPF followed by concurrent chemoradiotherapy with either docetaxel or ca

66 Concurrent chemoradiotherapy with hyperfractionated RT i

67 Concurrent chemoradiotherapy with or without surgery are

68 1998, many randomized studies that compared concurrent chemoradiotherapy with radiotherapy alone hav

69 well tolerated with concomitant boost RT or concurrent chemoradiotherapy with weekly CDDP.

70 luated whether induction chemotherapy before concurrent chemoradiotherapy would result in improved su

71 d that tirapazamine (TPZ) when combined with concurrent chemoradiotherapy yielded a promising median